Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 10;14(7):e0213414.
doi: 10.1371/journal.pone.0213414. eCollection 2019.

Cardiovascular effects of intravenous colforsin in normal and acute respiratory acidosis canine models: A dose-response study

Affiliations

Cardiovascular effects of intravenous colforsin in normal and acute respiratory acidosis canine models: A dose-response study

Takaharu Itami et al. PLoS One. .

Abstract

In acidosis, catecholamines are attenuated, and higher doses are often required to improve cardiovascular function. Colforsin activates adenylate cyclase in cardiomyocytes without beta-adrenoceptor. Here, six beagles were administered colforsin or dobutamine four times during eucapnia (partial pressure of arterial carbon dioxide 35-40 mm Hg; normal) and hypercapnia (ibid 90-110 mm Hg; acidosis) conditions. The latter was induced by CO2 inhalation. Anesthesia was induced with propofol and maintained with isoflurane. Cardiovascular function was measured by thermodilution and a Swan-Ganz catheter at baseline and 60 min after 0.3 μg/kg/min (low), 0.6 μg/kg/min (middle), and 1.2 μg/kg/min (high) colforsin administration. The median pH was 7.38 [range 7.33-7.42] and 7.01 [range 6.96-7.08] at baseline in the Normal and Acidosis conditions, respectively. Endogenous adrenaline and noradrenaline levels at baseline were significantly (P < 0.05) higher in the Acidosis than in the Normal condition. Colforsin induced cardiovascular effects similar to those caused by dobutamine. Colforsin increased cardiac output in the Normal condition (baseline: 3.9 ± 0.2 L/kg/m2 [mean ± standard error], low: 5.2 ± 0.4 L/kg/min2, middle: 7.0 ± 0.4 L/kg/m2, high: 9.4 ± 0.2 L/kg/m2; P < 0.001) and Acidosis condition (baseline: 6.1 ± 0.3 L/kg/m2, low: 6.2 ± 0.2 L/kg/m2, middle: 7.2 ± 0.2 L/kg/m2, high: 8.3 ± 0.2 L/kg/m2; P < 0.001). Colforsin significantly increased heart rate and decreased systemic vascular resistance compared to values at baseline. Both drugs increased pulmonary artery pressure, but colforsin (high: 13.3 ± 0.6 mmHg in Normal and 20.1 ± 0.2 mmHg in Acidosis) may have lower clinical impact on the pulmonary artery than dobutamine (high: 19.7 ± 0.6 in Normal and 26.7 ± 0.5 in Acidosis). Interaction between both drugs and experimental conditions was observed in terms of cardiovascular function, which were similarly attenuated with colforsin and dobutamine under acute respiratory acidosis.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Time course of study regimen.
After anesthesia and catheter preparation, four experimental sequences were randomized using a random number table, and then the dogs were stabilized for 30 min in each condition. Colforsin (1st. Dose: 0.3 μg/kg/min, 2nd. Dose: 0.6 μg/kg/min, 3rd. Dose: 1.2 μg/kg/min) and dobutamine (1st. Dose: 5 μg/kg/min, 2nd. Dose: 10 μg/kg/min, 3rd. Dose: 20 μg/kg/min) were infused 60 min. Cardiovascular parameters were measured at baseline and the end of each increment dose. The arrow indicates the measurement of cardiovascular parameters. The arrow-head indicates the measurement of blood gas and biochemical test.
Fig 2
Fig 2. The effects of colforsin and dobutamine on cardiac output, heart rate, systemic vascular resistance, and mean pulmonary artery pressure in normal and acidotic condition.
Upper left: cardiac index (CI), Upper right: heart rate (HR), Lower left: systemic vascular resistance index (SVRI), Lower right: mean pulmonary artery pressure (mPAP). In each graph, the horizontal axis shows the dosage of colforsin (Baseline, 1st. Dose: 0.3 μg/kg/min, 2nd. Dose: 0.6 μg/kg/min, 3rd. Dose: 1.2 μg/kg/min) and dobutamine (Baseline, 1st. Dose: 5 μg/kg/min, 2nd. Dose: 10 μg/kg/min, 3rd. Dose: 20 μg/kg/min). The white and black circle shows colforsin in normal and acidotic condition, respectively. The white and black triangle shows dobutamine in normal and acidotic condition, respectively. The plot and error bar shows mean value and standard error, respectively.

Similar articles

Cited by

References

    1. Lindner E, Metzger H. The action of forskolin on muscle cells is modified by hormones, calcium ions and calcium antagonists. Arzneimittelforschung. 1983;33(10):1436–41. - PubMed
    1. Metzger H, Lindner E. The positive inotropic-acting forskolin, a potent adenylate cyclase activator. Arzneimittelforschung. 1981;31(8):1248–50. - PubMed
    1. Hosono M. Cardiovascular effects of colforsin daropate hydrochloride, a novel drug for the treatment of acute heart failure. Nihon Yakurigaku Zasshi. 1999;114(2):83–8. - PubMed
    1. Schotola H, Toischer K, Popov AF, Renner A, Schmitto JD, Gummert J, et al. Mild metabolic acidosis impairs the β-adrenergic response in isolated human failing myocardium. Crit Care. 2012;16(4):R153 10.1186/cc11468 - DOI - PMC - PubMed
    1. Hagiya K, Takahashi H, Isaka Y, Inomata S, Tanaka M. Influence of acidosis on cardiotonic effects of colforsin and epinephrine: a dose-response study. J Cardiothorac Vasc Anesth. 2013;27(5):925–32. 10.1053/j.jvca.2012.09.019 - DOI - PubMed

Publication types

MeSH terms

Grants and funding

This work was supported by JSPS KAKENHI Grant Number JP 26861516. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.